RP Bio Inc.
Financials
Valuation Metrics
RP Bio Inc.'s Market Cap is ₩444B. At end of 2025 it was ₩641B. Ranked #1788 of 2,405 in KR market (top 74%), #1094 of 1,627 on KOSDAQ (top 67%), #192 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 44.37B KRW | KR#1,788/2,405 Sec#192/231 |
| Revenue | 141.42B KRW | KR#1,220/2,405 Sec#75/231 |
| Net Income | 6.73B KRW | KR#1,101/2,405 Sec#69/231 |
| Total Assets | 170.50B KRW | KR#1,414/2,405 Sec#106/231 |
| Net Assets | 116.75B KRW | KR#1,308/2,405 Sec#103/231 |
| Employees | 493 | KR#500/2,405 Sec#42/231 |
| Value | ||
| P/E | 6.60x | KR#583/2,405 Sec#25/231 |
| P/B | 0.38x | KR#608/2,405 Sec#23/231 |
| PEG | 0.05x | KR#329/2,405 Sec#18/231 |
| P/S | 0.31x | KR#660/2,405 Sec#18/231 |
| EV/EBITDA | 6.70x | KR#406/2,405 Sec#17/231 |
| FCF Yield | 16.40% | KR#430/2,405 Sec#10/231 |
| Profitability | ||
| ROE | 5.76% | KR#1,003/2,405 Sec#69/231 |
| ROA | 3.94% | KR#882/2,405 Sec#71/231 |
| Op. Margin | 5.28% | KR#926/2,405 Sec#70/231 |
| Revenue Growth | 9.55% | KR#922/2,405 Sec#91/231 |
| Earnings Growth | 121.62% | KR#352/2,405 Sec#23/231 |
| Financial Health | ||
| Debt Ratio | 46.04% | KR#898/2,405 Sec#103/231 |
| Total Debt | 16.00B KRW | KR#1,463/2,405 Sec#123/231 |
| FCF | 7.28B KRW | KR#804/2,405 Sec#50/231 |
| Cash | 10.28B KRW | KR#1,670/2,405 Sec#142/231 |
| Current Ratio | 1.42x | KR#1,261/2,405 Sec#135/231 |
| Net Debt/EBITDA | 0.77x | KR#708/2,405 Sec#47/231 |
| Dividend | ||
| Div. Yield | 0.97% | KR#1,149/2,405 Sec#67/231 |
| Performance | ||
| 1Y Return | -28.09% | KR#1,484/2,405 Sec#121/231 |
| 1M Return | -11.11% | KR#1,262/2,405 Sec#120/231 |
| From 52W High | -40.40% | KR#763/2,405 Sec#53/231 |
| 1Y MDD | -35.87% | KR#419/2,405 Sec#28/231 |
| Trading | ||
| Volume | 15,808 shares | KR#1,629/2,405 Sec#158/231 |
| Trading Value | 80.4M KRW | KR#1,523/2,405 Sec#158/231 |
| Foreign Own. | 2.09% | KR#1,589/2,405 Sec#152/231 |
| Per Share | ||
| EPS | 776 KRW | KR#822/2,405 Sec#59/231 |
| BPS | 13,472 KRW | KR#772/2,405 Sec#52/231 |
Company Info
RP Bio, established in 2016 through a spin-off and listed on KOSDAQ in 2022, is the sole domestic company inheriting Dr. RP Scherer's soft capsule manufacturing technology since 1983. The company manufactures and supplies various pharmaceuticals and health functional foods, including soft capsules, holding over 60% of the domestic soft capsule market share. RP Bio maintains long-term collaborations with major pharmaceutical companies, possesses 28 patents, and pursues global market expansion strategies based on its quality competitiveness.